Ethyl Pyruvate Ameliorates Experimental Autoimmune Myocarditis

Area of Science:

• Immunology
• Cardiology
• Pharmacology

Background:

• Experimental autoimmune myocarditis (EAM) is an immune-mediated heart disease.
• Ethyl pyruvate (EP) exhibits anti-inflammatory and immunomodulatory effects.

Purpose of the Study:

• To investigate the therapeutic effects of ethyl pyruvate (EP) on experimental autoimmune myocarditis (EAM).
• To determine EP's impact on immune cell infiltration and cytokine production in EAM.

Main Methods:

• EAM was induced in mice via immunization with heart-specific myosin-alpha heavy chain peptide.
• Ethyl pyruvate (EP) was administered intraperitoneally daily.
• Histological assessment, flow cytometry, and ELISA were used to evaluate EAM severity, immune cell populations, and cytokine levels.

Main Results:

• EP treatment significantly reduced immune cell infiltration and heart inflammation in EAM mice.
• EP decreased the number of immune cells, including antigen-presenting cells and T helper (Th)1/Th17 cells, in the heart and draining lymph nodes.
• Reduced production of IFN-γ and IL-17 was observed in EP-treated mice.

Conclusions:

• Ethyl pyruvate (EP) effectively restrains autoimmune responses in experimental autoimmune myocarditis (EAM).
• EP demonstrates therapeutic potential for myocarditis, warranting further clinical investigation.